Ambit Biosciences (AMBI) Stock Price, News & Analysis

Company Overview

Ambit Biosciences Corporation is a biopharmaceutical company. The Company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. The Company's lead drug candidate, quizartinib, is in Phase IIb clinical development in patients with relapsed/refractory acute myeloid leukemia (AML). The Company's second drug candidate in clinical development, AC410, is a potent, selective, orally-administered, small molecule inhibitor of Janus kinase 2 (JAK2) that has potential utility for the treatment of autoimmune and inflammatory diseases. The Company's third program consists of two selective small molecule compounds, AC708 and AC855, which inhibit the colony-stimulating factor-1 receptor (CSF1R), a receptor tyrosine kinase.

Key Stats

• Today's Range: $0.54 to $0.54
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 5,081 shs
• Market Capitalization: $29.91 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AMBI Stock Analysis - Frequently Asked Questions

How were Ambit Biosciences' earnings last quarter?

Ambit Biosciences Corporation (NASDAQ:AMBI) released its quarterly earnings results on Tuesday, May, 6th. The biopharmaceutical company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.47) by $0.03. The biopharmaceutical company had revenue of $0.03 million for the quarter, compared to analyst estimates of $3.50 million.

When did Ambit Biosciences IPO?

Ambit Biosciences (AMBI) raised $114 million in an IPO on Thursday, May 16th 2013. The company issued 8,125,000 shares at $13.00-$15.00 per share.

What other stocks do shareholders of Ambit Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ambit Biosciences investors own include Amarin (AMRN), Bristol Myers Squibb (BMY), Cytokinetics (CYTK), Delta Air Lines (DAL) and Fortress Biotech (FBIO).

Company Calendar

• Last Earnings: 5/06/2014
• Today: 5/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Industrials
• Industry: Sanitary services
• Sub-Industry: N/A
• Current Symbol: NASDAQ:AMBI
• CIK: 1131543
• Web: www.hpxcorp.com
• Phone: +1-858-3342100
• Fax: N/A
• Employees: 7,000
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 1.31
• Current Ratio: 2.07
• Quick Ratio: 1.97

Sales & Book Value

• Annual Sales: $518.81 million
• Price / Sales: 0.06
• Cash Flow: $0.08 per share
• Price / Cash Flow: 6.40
• Book Value: $4.90 per share
• Price / Book: 0.11

Miscellaneous

• Outstanding Shares: 55,430,000
• Free Float: 26,606,000
• Market Cap: $29.91 million
• Optionable: Not Optionable
• Beta: 0.55